Evidence map›Paper›PMID 39220325›Full record

ArticleBJR open2024

Three-dimensional dose prediction based on deep convolutional neural networks for brain cancer in CyberKnife: accurate beam modelling of homogeneous tissue.

Yuchao Miao, Ruigang Ge, Chuanbin Xie, Xiangkun Dai, Yaoying Liu, Baolin Qu, Xiaobo Li, Gaolong Zhang, Shouping Xu

Abstract read
In one paragraph

Article in BJR open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yuchao MiaoNational Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Ruigang GeDepartment of Radiation Oncology, the First Medical Center of the People's Liberation Army General Hospital, Beijing, 100853, China.
Chuanbin XieDepartment of Radiation Oncology, the First Medical Center of the People's Liberation Army General Hospital, Beijing, 100853, China.
Xiangkun DaiDepartment of Radiation Oncology, the First Medical Center of the People's Liberation Army General Hospital, Beijing, 100853, China.
Yaoying LiuSchool of Physics, Beihang University, Beijing, 102206, China.
Baolin QuDepartment of Radiation Oncology, the First Medical Center of the People's Liberation Army General Hospital, Beijing, 100853, China.
Xiaobo LiDepartment of Radiation Oncology, Fujian Medical University Union Hospital, Fuzhou, Fujian, 350001, China.
Gaolong ZhangSchool of Physics, Beihang University, Beijing, 102206, China.
Shouping XuNational Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.ORCID https://orcid.org/0000-0003-3189-9680

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Accurate beam modelling is essential for dose calculation in stereotactic radiation therapy (SRT), such as CyberKnife treatment. However, the present deep learning methods only involve patient anatomical images and delineated masks for training. These studies generally focus on traditional intensity-modulated radiation therapy (RT) plans. Nevertheless, this paper aims to develop a deep CNN-based method for CyberKnife plan dose prediction about brain cancer patients. It utilized modelled beam information, target delineation, and patient anatomical information. Methods: This study proposes a method that adds beam information to predict the dose distribution of CyberKnife in brain cases. A retrospective dataset of 88 brain and abdominal cancer patients treated with the Ray-tracing algorithm was performed. The datasets include patients' anatomical information (planning CT), binary masks for organs at risk (OARs) and targets, and clinical plans (containing beam information). The datasets were randomly split into 68, 6, and 14 brain cases for training, validation, and testing, respectively. Results: Our proposed method performs well in SRT dose prediction. First, for the gamma passing rates in brain cancer cases, with the 2 mm/2% criteria, we got 96.7% ± 2.9% for the body, 98.3% ± 3.0% for the planning target volume, and 100.0% ± 0.0% for the OARs with small volumes referring to the clinical plan dose. Secondly, the model predictions matched the clinical plan's dose-volume histograms reasonably well for those cases. The differences in key metrics at the target area were generally below 1.0 Gy (approximately a 3% difference relative to the prescription dose). Conclusions: The preliminary results for selected 14 brain cancer cases suggest that accurate 3-dimensional dose prediction for brain cancer in CyberKnife can be accomplished based on accurate beam modelling for homogeneous tumour tissue. More patients and other cancer sites are needed in a further study to validate the proposed method fully. Advances in knowledge: With accurate beam modelling, the deep learning model can quickly generate the dose distribution for CyberKnife cases. This method accelerates the RT planning process, significantly improves its operational efficiency, and optimizes it.

Indexed as

brain cancerCyberKnifedeep CNNsdose prediction

Identifiers

PMID39220325
PMCPMC11364489

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.